Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Yamanouchi describes new CRF2 receptor antagonists and their use

Sep. 28, 1999

Selective alpha2B-adrenoceptor ligands developed at Hokuriku

Sep. 28, 1999

Blockade of terminal 5-HT autoreceptor by selective 5-HT1B receptor inverse agonist SB-236057

Sep. 27, 1999

First patient receives transplanted porcine fetal neural cells in Diacrin's phase I study

Sep. 27, 1999

Wyeth-Ayerst provides updated information on stroke Rx

Sep. 27, 1999

Citalopram exerts its in vitro and in vivo effects through the (S)-enantiomer

Sep. 24, 1999

Enrollment completed for phase IIb memantine trial in diabetic peripheral neuropathy

Sep. 24, 1999

SB-269652 selectively antagonizes dopamine D3 receptors implicated in schizophrenia

Sep. 24, 1999

First treatment for postherpetic neuralgia reaches U.S. market

Sep. 24, 1999

Potent group II metabotropic glutamate receptor agonists in the Taisho pipeline

Sep. 24, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...